Authors/Disclosures
|
Dan Hesse
(Biogen Idec Denmark A/S)
|
No disclosure on file |
|
Ariel Antezana, MD
(NeuroMedical clinic of cenla)
|
Dr. Antezana has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Antezana has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS. Dr. Antezana has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for EMD Serono. Dr. Antezana has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BMS. Dr. Antezana has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. |
|
Hyun-Sik Yang, MD
(Brigham and Women'S Hospital)
|
Dr. Yang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Axon advisors. The institution of Dr. Yang has received research support from National Institutes of Health. Dr. Yang has received personal compensation in the range of $500-$4,999 for serving as a study section member with National Institutes of Health. |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
Per Solberg Sorensen, MD, PhD, FAAN
(Rigshospitalet Glostrup)
|
Dr. Sorensen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Sorensen has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Sorensen has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Sorensen has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TEVA. |
|
Finn Sellebjerg, MD
(Copenhagen University Hospital Rigshospitalet)
|
Dr. Sellebjerg has received personal compensation for serving as an employee of Danish Multiple Sclerosis Society. Dr. Sellebjerg has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Sellebjerg has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Sellebjerg has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Sellebjerg has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Sellebjerg has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Genzyme. Dr. Sellebjerg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Sellebjerg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Sellebjerg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Sellebjerg has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Gangsted Foundation. Dr. Sellebjerg has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Warwara Larsen Foundation. The institution of Dr. Sellebjerg has received research support from Biogen. The institution of Dr. Sellebjerg has received research support from Merck. The institution of Dr. Sellebjerg has received research support from Novartis. The institution of Dr. Sellebjerg has received research support from Sanofi Genzyme. Dr. Sellebjerg has received publishing royalties from a publication relating to health care. |